Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on October 27th, 2017 by Sherry WinterPharmacovigilance
In the description of the FDA Adverse Event Reporting System (FAERS), the agency states that “voluntary and mandatory reporting plays an important role in the FDA’s post-market safety monitoring.” Continue reading “Why a reliable FAERS searching capability is essential for pharma companies” »
Posted on October 25th, 2017 by Christy J. WilsonChemistry
In many people’s minds, the classic image of the chemist is still someone in a lab coat standing over a burner, while chemistry itself tends to evoke thoughts of equations on chalkboards and fluids in beakers. But the reality is that these images are a bit outdated Continue reading “Chemists: Unsung Innovators” »
Posted on October 23rd, 2017 by Betsy DavisPharma R&D
A widespread outbreak in 2015 had people across the globe concerned about Zika (ZIKV), an infectious disease mainly spread through mosquito bites. In 2016 we took a look at some of the top scientific research about the virus being shared online. Continue reading “The Five Most-Talked about Zika Articles in 2017” »
Posted on October 20th, 2017 by Tim HoctorPharma R&D
With the many highly effective vaccines that have been created over the last several decades, it can be easy (particularly for those in America and other developed countries) to fall into the trap of thinking that we are living in a world where infectious disease is not that big of a threat. Continue reading “Big Data vs. Infectious Disease” »
Posted on October 18th, 2017 by Betsy DavisPharma R&D
There is nothing that pharmaceutical companies guard more fiercely than their intellectual property. Devising and patenting the next big wonder drug is every company’s dream Continue reading “Pharma Companies United By a Need for Common Data Models” »
Posted on October 16th, 2017 by Betsy DavisPharma R&D
In Norway, a land that evokes images of rough-hewn Scandinavians, icy natural beauty and old wooden Viking ships, there is in fact a great deal of investment currently being put into not-so-rugged things like cutting-edge new labs and state-of-the-art scientific research.
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.